• ConvaTec (Skillman, New Jersey) reported the launch of a new campaign and best practice statement supporting Versiva XC gelling foam dressing. The Versiva XC is the only cover dressing to contain ConvaTec's Hydrofiber Technology; and the company claims the Versiva XC dressing transforms wounds through its unique gelling action. This action enables dressings containing Hydrofiber Technology to lock in exudates and its harmful components and contour closely to the wound bed, in response to changing wound conditions. ConvaTec dressings with Hydrofiber Technology gel on contact with fluid, providing clinicians and patients with substantial wound care benefits.

• Vicor Technologies (Boca Raton, Florida) said that the U.S. Army Institute of Surgical Research (USAISR), will present findings from trials of Vicor's PD2i VS (Vital Sign) that have been performed under a collaborative agreement between Vicor and the USAISR at Smart Monitoring 2009. The two presentations will a) detail the use of Vicor's PD2i VS as a new vital sign diagnostic that more accurately risk stratifies trauma severity and the probability of survival in the critically injured, and b) provide a review of findings from trials conducted under the Collaborative Research and Development Agreement (CRADA) between Vicor and the USAISR begun in January 2008.